Angiotech acquires California -based Cohesion

Guest Contributor
October 21, 2002

Vancouver’s Angiotech Pharmaceuticals Inc has announced its intention to acquire Cohesion Technologies Inc, Palo Alto CA, in an all stock merger transaction worth US$42 million. The deal is expected to close by Q1/03, creating a major player in the emerging field of bioactive devices and implants. Cohesion (formerly Collagen Corp) brings to the merger a portfolio that includes four biomaterials and three approved products involving composites, sealants and adhesives. It also has strong R&D capabilities, regulatory and clinical experience and a specialized US sales force. The merger is expected to dramatically accelerate Angiotech’s product development pipeline, which focuses on medical device coatings and treatments for chronic inflammatory disease through reformulation paclitaxel, an anticancer drug....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.